BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 24637687)

  • 1. Efficacy and tolerability of micafungin monotherapy for candidemia and deep-seated candidiasis in adults with cancer.
    Farmakiotis D; Tarrand JJ; Kontoyiannis DP
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3526-9. PubMed ID: 24637687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of micafungin for the treatment of invasive candidiasis and candidaemia in patients with neutropenia.
    Chandrasekar P; Sirohi B; Seibel NL; Hsu JW; Azie N; Wu C; Ruhnke M
    Mycoses; 2018 May; 61(5):331-336. PubMed ID: 29364548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species.
    Cornely OA; Vazquez J; De Waele J; Betts R; Rotstein C; Nucci M; Pappas PG; Ullmann AJ
    Mycoses; 2014 Feb; 57(2):79-89. PubMed ID: 23786573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Micafungin versus anidulafungin in critically ill patients with invasive candidiasis: a retrospective study.
    van der Geest PJ; Hunfeld NG; Ladage SE; Groeneveld AB
    BMC Infect Dis; 2016 Sep; 16():490. PubMed ID: 27634140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of New Strategies for Echinocandins: Progress in Translational Research.
    Walsh TJ; Azie N; Andes DR
    Clin Infect Dis; 2015 Dec; 61 Suppl 6():S601-3. PubMed ID: 26567276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B.
    Dupont BF; Lortholary O; Ostrosky-Zeichner L; Stucker F; Yeldandi V
    Crit Care; 2009; 13(5):R159. PubMed ID: 19804626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors related to survival and treatment success in invasive candidiasis or candidemia: a pooled analysis of two large, prospective, micafungin trials.
    Horn DL; Ostrosky-Zeichner L; Morris MI; Ullmann AJ; Wu C; Buell DN; Kovanda LL; Cornely OA
    Eur J Clin Microbiol Infect Dis; 2010 Feb; 29(2):223-9. PubMed ID: 20013016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Micafungin in invasive candidiasis among oncohematological patients].
    Jarque I; Angel Sanz M
    Rev Iberoam Micol; 2009 Mar; 26(1):75-7. PubMed ID: 19463282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Candidemia in the intensive care unit: analysis of direct treatment costs and clinical outcome in patients treated with echinocandins or fluconazole.
    Heimann SM; Cornely OA; Wisplinghoff H; Kochanek M; Stippel D; Padosch SA; Langebartels G; Reuter H; Reiner M; Vierzig A; Seifert H; Vehreschild MJ; Glossmann J; Franke B; Vehreschild JJ
    Eur J Clin Microbiol Infect Dis; 2015 Feb; 34(2):331-8. PubMed ID: 25213718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.
    Pappas PG; Rotstein CM; Betts RF; Nucci M; Talwar D; De Waele JJ; Vazquez JA; Dupont BF; Horn DL; Ostrosky-Zeichner L; Reboli AC; Suh B; Digumarti R; Wu C; Kovanda LL; Arnold LJ; Buell DN
    Clin Infect Dis; 2007 Oct; 45(7):883-93. PubMed ID: 17806055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin:review of the literature.
    Glöckner A
    Eur J Med Res; 2011 Apr; 16(4):167-79. PubMed ID: 21486731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia.
    Andes D; Ambrose PG; Hammel JP; Van Wart SA; Iyer V; Reynolds DK; Buell DN; Kovanda LL; Bhavnani SM
    Antimicrob Agents Chemother; 2011 May; 55(5):2113-21. PubMed ID: 21300835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of micafungin vs. liposomal amphotericin B (LAmB) for the treatment of candidaemia and invasive candidiasis (IC).
    Neoh CF; Liew D; Slavin MA; Marriott D; Chen SC; Morrissey O; Stewart K; Kong DC
    Mycoses; 2013 Sep; 56(5):532-42. PubMed ID: 23496163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacoeconomic evaluation of micafungin versus caspofungin as definitive therapy for candidaemia and invasive candidiasis (IC) in Turkey.
    Neoh CF; Senol E; Kara A; Dinleyici EC; Turner SJ; Kong DCM
    Eur J Clin Microbiol Infect Dis; 2018 Mar; 37(3):537-544. PubMed ID: 29185089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of micafungin versus caspofungin for the treatment of candidaemia and invasive candidiasis.
    Neoh CF; Liew D; Slavin MA; Marriott D; Chen SC; Morrissey O; Stewart K; Kong DC
    Intern Med J; 2013 Jun; 43(6):668-77. PubMed ID: 23461421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy and safety of systemic antifungal agents for candidemia: a systematic review with network meta-analysis and multicriteria acceptability analyses.
    Domingos EL; Vilhena RO; Santos JMMF; Fachi MM; Böger B; Adam LM; Tonin FS; Pontarolo R
    Int J Antimicrob Agents; 2022 Aug; 60(2):106614. PubMed ID: 35691603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relationship between the effectiveness and dose of micafungin in the treatment of candidemia].
    Sugawara T; Murakami N; Uetake N; Matsumoto S; Miyamori S; Okamoto R; Hiraki K
    Yakugaku Zasshi; 2014; 134(3):433-8. PubMed ID: 24584025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species.
    Ou HT; Lee TY; Chen YC; Charbonneau C
    BMC Infect Dis; 2017 Jul; 17(1):481. PubMed ID: 28693479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs: review of the literature.
    Wilke M
    Eur J Med Res; 2011 Apr; 16(4):180-6. PubMed ID: 21486732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EMPIRICUS micafungin versus placebo during nosocomial sepsis in Candida multi-colonized ICU patients with multiple organ failures: study protocol for a randomized controlled trial.
    Timsit JF; Azoulay E; Cornet M; Gangneux JP; Jullien V; Vésin A; Schir E; Wolff M
    Trials; 2013 Nov; 14():399. PubMed ID: 24261608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.